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Structure-Activity Relationships of
Estrogens
by V. Craig Jordan,* Shubhra Mittal,* Barbara Gosden,*
Rick Koch,* and Mara E. Lieberman*t
The last 50 years has seen an exponential rise in the published reports about estrogen action. The model
to describe the early events in the mechanism of action of estrogens via the estrogen receptor is updated
in this paper to incorporate some of the recent data on the subcellular localization of the receptor. New
evidence suggests that the receptor is a nuclear protein, so it appears that estrogens must first diffuse into
the nuclear compartment to initiate estrogen action via the receptor complex. This review traces the
development ofpotent estrogenic compounds by the study oftheir structure-activity relationships. Studies
of structure-activity relationships in vivo using Allen Doisy or 3-day uterine weight tests can provide
much valuable information, but the assays suffer from the complex problems of pharmacokinetics and
metabolic transformation. Studies in vitro using primary cultures ofrat pituitary or uterine cells to assay
the ability of a compound to induce prolactin synthesis or progesterone receptor synthesis, respectively,
can provide essential information about the structural requirements for a compound to produce estrogenic
effects. Nevertheless, it should be pointed out that studies in vivo are required to determine whether a
compound is metabolically activated to an estrogen. Estrogen receptor binding models are presented to
describe the changes in a molecule that will predict high affinity forthe ligand and agonist, partial agonist
and antagonist properties of the ligand-receptor complex. Most estrogenic pesticides and phytoestrogens
comform to the predictions of the estrogen receptor binding model.
Introduction
It is now more than half a century since the first
compound, with known chemical structure, was shown
to produce an estrogenic effects in animals (1). Since
that time, thousands ofcompounds have been screened
for estrogenic activity. In the past quarter century the
early events involved in the molecular mechanism of
action ofestrogens in their target tissues (e.g., vagina,
uterus, pituitary gland or breast), via the estrogen re-
ceptor, have been described (2-5). The aim ofthis paper
is to review the evolution of structure-activity rela-
tionship studies and suggest estrogen receptor models
topredictbiological activity. Abriefsurveyofthe struc-
ture activity relationships ofphytoestrogens, pesticides
and antiestrogens will be used to demonstrate the re-
current molecular features necessary for a compound to
bind to the estrogen receptor and/or to produce a con-
formational change in the receptor complex that will
initiate agonist or antagonist actions.
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Historical Perspective: The First 25
Years
The pioneering studies by Sir Charles Dodds laid the
foundation for all the subsequent research on the struc-
ture activity relationships of nonsteroidal estrogens. The
1930s saw a remarkable expansion of knowledge that
culminated in the description of the optimal structural
requirements in a simple molecule to produce estrogen
action. The first compound of known structure (1-keto-
1,2,3,4-tetrahydrophenanthrene) (Fig. 1, compound 2)
to be found to have estrogenic activity (1) was tested
because of its structural similarity to the presumed
structure of ketohydroxy estrin (Fig. 1, compound 1).
As it turned out, the structure of the natural steroid
(estrone) was incorrect, but this did not matter; the fact
that nonsteroidal compounds can exhibit estrogenic
properties was established. A phenanthrene nucleus was
laterfound to be unnecessary forestrogenic activity (6).
Simple bisphenolic compounds are active (Fig. 1, com-
pounds 3-6) and, as will be seen later in the review,
this is a recurrent feature of many nonsteroidal estro-
gens. The finding that hydroxystilbenes (Fig. 1, com-
pounds 7-9) possess potent estrogenic activity provided
a valuable clue that stimulated a systematic investiga-JORDAN ET AL.
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FIGURE 1. Formulae of compounds found, in the 1930s, to have es-
trogenic activity in vivo. Compound 1 was believed to be the
molecular structure of ketohydroxyestrin (estrone). This is now
known to be incorrect.
tion of analogs to optimize the potency. At this time,
an interesting side issue occurred that deserves com-
ment, as it illustrates how parallel research endeavors
can eventually reach the same conclusions. Anol, a sim-
ple phenol derived from anethole (Fig. 2), was reported
to possess extremely potent estrogenic activity with 1
,ug capable of inducing estrus in all rats (7). These re-
sults were not confirmed with different preparations of
anol (8,9), but it was found that dimerization of anol to
dianol (Fig. 2) can occur and this impurity, which was
known to have potent estrogenic (10) properties, was
the compound responsible for the controversy (11). At
this time, Dodds reported (12) that diethyl substitution
at the ethylenic bond ofstilbestrol (Fig. 2) produces an
extremely potent estrogen (12,13); other substitutions
produce less active compounds (14). The structural sim-
ilarity between diethylstilbestrol and estradiol (the for-
mula was established by 1938) was noted (12), but an
attempt to mimic the rigid steroid structure by the syn-
thesis of dihydroxyhexahydrochrysene (Fig. 2) demon-
strated a drop in estrogenic potency. Dihydroxy-
hexahydrochrysene is approximately 1/2000 as potent
as diethylstilbestrol.
There was considerable interest in the development
of a long-acting synthetic estrogen because of the po-
tential for clinical application. The duration of action of
diethylstilbestrol can be increased dramatically by es-
terification of the phenolic groups (15). A 10-Rg dose of
diethylstilbestrol dipropionate can produce estrus for
more than 50 days, while the phenol at the same dose
is active for only 5 days. The simple hydrocarbon tri-
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FIGURE 2. Formulae ofnonsteroidal compounds with estrogenic (or
suspected) activity in vivo.
phenylethylene is a weakly active estrogen (16), but 10
mg can produce vaginal cornification in mice for up to
9 weeks. Replacement of the free ethylenic hydrogen
withchlorine (Fig. 1)increasesthe potencyand duration
ofaction by subcutaneous administration (17), but when
administered orally, triphenylchloroethylene has a sim-
ilar duration of action as diethylstilbestrol or estradiol
benzoate. In the search for orally active agents, Robson
and Schonberg (18) showed that DBE (Fig. 2) was very
effective by the oral route. The long duration of action
is related to depot formation in body fat (19), but DBE
did not reach clinical trial. The related compound, trian-
isylchloroethylene (TACE) is, however, available clin-
ically as a long-acting estrogen (Fig. 2). TACE is stored
in body fat for prolonged periods (20-22).
The first 25 years established many ofthe important
structural features that govern the potency and dura-
tion of action of estrogens. Investigations for the next
25 years focused upon the subcellular mechanism of es-
trogen action.
Estrogen Action
The reason for the target site specificity of the es-
trogens remained obscure until the synthesis oftritium-
labeled compounds with high specific activity. The syn-
thesis of [3H]hexestrol (reduction of diethylstilbestrol
with tritiumand apalladiumcatalyst) by Glascockwork-
ing with Sir Charles Dodds (23) and the subsequent
observation that there was binding of hexestrol in the
uterus, vagina, mammary glands and pituitary gland of
immature female goats and sheep (24) provided the first
evidence for the target tissue localization of estrogens.
The subsequent fundamental study by Jensen and Ja-
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FIGURE 3. Subcellular models ofestrogen action. Estrogen (E) dissociates from plasma proteins (P) and diffuses into the target cell. In Model
1 the receptor (R) is located in the cytoplasm and in Model 2 the receptor is in the nuclear compartment. In both models the receptor
complex is activated before initiating protein synthesis and finally cell division. The fate of the receptor is at present unknown; it may be
recycled, destroyed (processed) or resynthesized.
cobson (2) ofthe distribution and binding of [3H]estradiol
in the immature rat demonstrated that estradiol selec-
tively binds to, and is retained by, the uterus, vagina,
and pituitary gland. These studies suggested that there
is a specific receptor for estradiol in its target tissues.
The biochemical identification of an estrogen binding
protein in the immature rat uterus and the observation
that [3H]estradiol becomes located in the nucleus ofthe
cell provided a model to describe the initiation of es-
trogen-stimulated events. The evidence for an estrogen
receptor system has been reviewed (3,4), and the model
illustrated in Figure 3 has been proposed. The estrogen
dissociates from plasma proteins and readily diffuses
into the cell. The cytoplasmic estrogen receptor binds
the ligand and the resulting receptor complex is acti-
vated before translocation to the nucleus. Interaction
with nuclear acceptors results in the activation ofRNA
and DNA polymerases to initiate subsequent protein
synthesis and cellproliferation, respectively. There are,
however, an increasingnumber ofobservations that are
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inconsistent with the classical two-step hypothesis. These
reports have been reviewed (5). Two recent innovative
approaches tothe question ofthe subcellularlocalization
of unoccupied estrogen receptor deserve comment.
Monoclonal antibodies raised to the estrogen receptor
arebeingused astagsforimmunohistochemical studies.
The antibody is linked to a peroxidase enzyme system
to visualize the receptor, which appears to be located
exclusively in the nuclear compartment, even in the
absence of estrogen (25). The other approach has been
to enucleate estrogen receptor containing GH3 rat pi-
tuitary tumor cells with cytochalasin B. Unoccupied re-
ceptors are observed in nucleoplasts rather than
cytoplasts (26). Although itispossiblethatthese studies
are generating artifactual results, the simplified model
ofestrogen action illustrated in Figure 3 should also be
considered to represent subcellular events in vivo.
Testing Methods for Estrogens
The Allen-Doisy test (27) depends upon the induction
ofvaginalcornification incastrateanimals60-80hrafter
the subcutaneous administration ofestrogens. A colony
of animals is ovariectomized and used for assays two
weeks later. To maintain the sensitivity of the colony
and retard atrophy of the uterus and vagina (28), the
animals are primed with 1 jig estradiol (SC) every 6
weeks. The animals are not used for 2 weeks following
eitherpriming orexperimental use. However, itis often
wise to screen the animals by the vaginal smear tech-
nique to check for incomplete ovariectomy or test com-
pounds with prolonged biological activity.
Direct administration of estrogens into the vagina
increases the sensitivity of the Allen-Doisy test and
cornification occurs earlier since the response is not de-
pendent upon distribution and metabolism (29,30). Em-
mens (29-32) has assayed and evaluated the structural
derivatives of stilbene and triphenylethylene by both
intravaginal and systemic Allen-Doisy tests. This early
FIGURE 5. Receptor binding and uterotrophic activity of estradiol,
ethinylestradiol, and mestranol: (A) inhibition of the binding of
[3H]estradiol to rat uterine estrogen receptors in vitro by ethinyl
estradiol, estradiol, and mestranol; (B) uterotrophic activity of
ethinyl estradiol, estradiol, and mestranol in the 3-day immature
rat uterine wet weight test. Data adapted from Allen et al. (49).
work accurately established the relative potency ofthe
test compounds.
Martin and Claringbold (33) developed the intrava-
ginal assay to study the early events of estrogen stim-
ulation by using the increase in vaginal mitoses and
vaginal epithelium thickening as measures ofthe estro-
genic response. Martin (34) further showed that the
reduction of 2,3,5-triphenyltetrazolium chloride to for-
mazan in epithelial cells ofthe vagina followingthe local
application of estrogens could form the basis of a sen-
sitive assay procedure for early estrogenic events.
The increase in uterine weight ofyoung castrate rats
was used to determine systemic estrogen activity by
Bulbring and Burn (35). The preparation of castrate
animals has been found to be an unnecessary step, and
immature rats or mice are usually used (36,37). Estro-
gens induce a rapid early imbibition of water by the
uterus, and this effect has been used in the 6-hr assay
ofestrogens by Astwood (38). However, this technique
cannot distinguish between full estrogens and partial
agonists and also suffers from differences in the release
of test compounds from the injection site which will
ultimately affect the time course of the uterine re-
sponse. Most assays utilize a 3-day injection technique
to stimulate full uterine growth (39).
Potentialestrogenicactivitycanbeinferredforacom-
pound byitsabilitytoinhibitthebindingof[3H]estradiol
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toits target tissuesinvivo (40,41). However, manynon-
steroidal antiestrogens produce the same effect (42,43)
so this effect cannot be assumed to predict biological
activity. Similarly, the ability of a compound to inhibit
the binding of [3H]estradiol to estrogen receptors in
vitro suggests a potential mechanism of action via the
estrogen receptor but again this cannot predict biolog-
ical activity, i.e., agonist or antagonist actions (44).
The evaluation of a compound to inhibit the binding
of[3H]estradiol to the estrogen receptor in vitro (45,46)
must be used in combination with an evaluation of es-
trogenic properties in vivo. This approach will avoid the
misclassification of a compound as inactive based upon
a low potential to bind to receptors in vitro, only to find
it is converted to a potent estrogen in vivo. Mestranol
(Fig. 4) has a very low affinity for estrogen receptors
in vitro, but in vivo it is rapidly demethylated to the
potent estrogen ethinyl estradiol (47,48). These prin-
ciples are illustrated in Figure 5. Demethylation of
methyl ethers to phenols is aprimary route ofmetabolic
activation for several phytoestrogens and insecticides.
While studies in vivo are necessary to evaluate the
potential for the metabolic activation of a compound,
studies of structure-activity relationships require pre-
cise assays in vitro where the concerns of metabolic
transformation can be minimized. We are currently us-
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ing two assay techniques in vitro: a prolactin synthesis
assay (50,51) and progesterone receptor synthesis assay
(52), in combination with a determination ofthe relative
bindingaffinityofacompound fortheestrogenreceptor.
Representative results are illustrated in Figure 6 for
the estrogens estradiol, estrone and estriol and com-
pared with the estrogen antagonist 4-hydroxytamoxi-
fen. This antiestrogen has a high affinity for the estrogen
receptor (53). Several points can be made about the
results of these studies. The assays in vitro avoid the
problems of pharmacokinetics encountered with the
administration of short-acting estrogens like estriol in
uterine weight tests (54). Potency appears to be low in
traditional assays in vivo because the steroid is cleared
before a biological effect can be produced. Sustained
release preparations that are implanted into animals
demonstrate high biologicalactivity forestriol (54). This
principle is readily illustrated in the assays in vitro where
cells are continuously exposed to ligands to initiate es-
trogen-stimulated prolactin (Fig. 6B) or progesterone
(Fig. 6C) receptor synthesis. Clearly polyphenolic es-
trogens in the environment will be rapidly excreted fol-
lowing single daily administration to immature rats or
mice. As a result, the compounds may produce no bi-
ological effects in vivo but may be shown to have bio-
logical effect in the assay in vitro. These assays in vitro
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FIGURE 6. Receptor binding and biological activity in vitro ofestradiol, estrone, estriol, and 4-hydroxytamoxifen: (A) inhibition ofthe binding
of['H]estradiol to rat uterine estrogen receptors in vitro by 4-hydroxytamoxifen, estradiol, estrone, and estriol; (B) increase in the percent
prolactin synthesis produced by the culture ofdispersed cells from immature rat pituitary glands with increasing concentrations ofestradiol,
estriol, and estrone; (C) percent increase (over control) ofprogesterone receptor in cultures ofdispersed cells from immature rat uteri with
increasing concentrations of estradiol, estriol, and estrone; (D) percent decrease of estradiol (1 nM)-stimulated progesterone receptor in
cultures of dispersed cells from immature rat uteri produced by increasing concentrations of 4-hydroxytamoxifen.
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mimic continual exposure of an organ to a particular
compound.
The result with the antiestrogen 4-hydroxytamoxifen
(Fig. 6D) is ofinterest because it is a complete estrogen
antagonist and does not stimulate either progesterone
receptor or prolactin synthesis in vitro (44,51). 4-Hy-
droxytamoxifen stimulates progesterone receptor syn-
thesis in the rat uterus in vivo (55,56). The pharma-
cological properties of antiestrogens in vitro have per-
mitted the development of drug receptor models of es-
trogen and antiestrogen. These will be considered in
the final section following a brief survey of the struc-
ture-activity relationships of phytoestrogens and se-
lected estrogenic pesticides.
Phytoestrogens
Plants (57) and fungal contaminants of stored grain
(58) contain estrogens thataresuspected ofcontributing
to infertility problems in farm animals. There is also
the possibility that phytoestrogens in the diet can con-
tribute to the growth ofhormone-dependent breast tu-
mors in postmenopausal patients (59). Other than the
potentially harmful effects of estrogens, they are ap-
parently important to improve the quality of meat.
Grazing animals in areas that are rich in phytoestrogens
could provide economic advantages.
There are three major chemical types of phytoestro-
gens in plants: flavones, isoflavones and coumestans.
The formula of two estrogenic compounds, genistein
(isoflavone) and coumestrol (coumestan), are usually de-
picted as shown in Figure 4. However, for discussion
purposes the structures of a range of phytoestrogens
have been redrawn in a novel fashion to compare bio-
logical potency-receptor binding and structure (Fig. 7).
The isoflavone derivatives have attracted much at-
tention as estrogenic compounds in clover. The early
structure-activity relationships studies were reviewed
by Bradbury and White (60). Genistein is the most ac-
tive estrogen of this group with the highest binding
affinity (RBA 0.9) for the estrogen receptor (61). The
methoxy derivative, Biochanin A, does not bind to the
estrogen receptor, but is estrogenic in vivo (61,62) Sim-
ilarly, diadzein has a higher binding affinity for the es-
trogen receptor than the methoxy derivative,
formononetin; both are weak estrogens in vivo (61,62).
(c.f., ethinylestradiol and mestranol). The metabolism
of formonentin and Biochanin A by micro/organisms in
the sheeprumenhasbeendescribed (63); however, diad-
zein is further reduced to equol, a weak estrogen (64)
that can be crystallized from urine.
Recently, a novel compound, enterolactone (HPMF),
has been isolated from human urine (65,66) (Fig. 8). No
biological properties or function have been ascribed for
enterolactone, butitappearstobe aproductofmicrobial
metabolic transformation in the intestine (67,68). In
testing this compound we detected no estrogenic prop-
erties in a 3-day Rubin test using immature female rats
and no ability to inhibit [3H]estradiol binding to uterine
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to as HPMF (65).
estrogen receptors. However, we made two interesting
observations that might have clinical implications. The
nonsteroidal antiestrogen, tamoxifen, inhibits estradiol-
stimulated prolactin synthesis by immature rat pitui-
tary cells in vitro (Fig. 9A). HPMF does not affect
estradiol-stimulated prolactin synthesis, but is signifi-
cantly estrogenic at 10 ,uM (Fig. 9A). In another test
that uses growth of MCF7 breast cancer cells as an
endpoint, tamoxifen alone inhibits the growth of the
cells, but this can readily be reversed with estradiol
(69). HPMF (10 ,uM) can also reverse the inhibitory
effect of tamoxifen on the growth of MCF7 cells (Fig.
9B). Clearly, high circulating levels of HPMF might be
detrimental to patients undergoing antiestrogen ther-
apy for breast cancer.
The flavones are very weak estrogens. The methoxy-
flavone, tricin, is a constituent of alfalfa (70) and very
weakly estrogenic in the mouse. Several flavones (Ii-
queritigenin, naringenin and hesperitin) have been
shown to be inactive as estrogens in the immature rat;
however, 4',6-dihydroxyflavone (Fig. 7) is an active es-
trogen by subcutaneous administration but not orally
(71). It is postulated that 4',6-hydroxyflavone is con-
verted to the ring opened chalconoid by alkali in the
intestine. [N.B. The authors, Wenzel and Rosenberg
(71), mistakenly state in their summary that 4',6-di-
hydroxyflavone is only active orally and not subcuta-
neously as their data show.] However, a chalconoid,
phloretin (Fig. 7), has been shown (72) to have estro-
genic properties in immature mice if administered sub-
cutaneously for 10 days; therefore, conversion offlavones
to chalconoids cannot completely explain their lack of
estrogenicity following oral administration.
Coumesterol (Fig. 7) is the most potent ofthe estro-
gens in forage crops (73) and, consistent with this ob-
servation, has a higher binding affinity for the estrogen
receptorthan genistein (61,74). Aspreviously discussed
for genistein, conversion ofcoumesterol to its methoxy
derivatives prevents binding to the estrogen receptor
(74). Medicagol does not bind to the estrogen receptor
(74), whichisconsistent withthereceptorbindingmodel
that appears to depend upon a phenolic group in the 4'
position of isoflavones and the 12 positions of coumes-
tans. In contrast, sativol does not inhibit [3H]estradiol
binding (74). This seems to be anomalous, because the
12-hydroxyl is free and the 7-hydroxyl is methylated;
however, the 6-phenol might be responsible for this
effect.
The Fusarium fungus produces an estrogenic ma-
crolide, zearalenone, which has been shown to have low
binding affinity for estrogen receptors from rat uterus
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FIGURE 9. Biological activity of HPMF: (A) Inhibition of estradiol
(1 nM)-stimulated prolactin synthesis by tamoxifen. HPMF did
notinhibit estradiol-stimulated prolactin synthesis but 10 ,uM stim-
ulated prolactin synthesis in immature rat pituitary cells in cul-
ture. (B) Inhibition ofthe growth of MCF7 breast cancer cells by
tamoxifen (1 ,uM). Estradiol (10 nM) or HPMF (10 ,uM) reversed
the effect of tamoxifen on cell growth.
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FIGURE 10. Structural derivatives of zearalenone.
(75), mammarygland (76), and the MCF-7 human breast
cancer cell line (59). The structural requirements for
receptorbinding have been described (75) (Fig. 10). The
cis and trans isomeric forms ofzearalenone, zearalenol,
and zearalanol all have a similar, low binding affinity
for estrogen receptors. The 8'-hydroxyzearalenone and
6'-aminozearalene are inactive in vivo and in vitro. It
is not, however, possible to state with assurance that
the 4-phenolic hydroxyisimportant forreceptorbinding.
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FIGURE 11. Formulae of some polychlorinated pesticides and the
hydroxy metabolites of methoxychlor.
Pesticides
The chlorinated pesticides are known to alter the re-
productive capacity of animals by an interaction with
estrogen target tissues (77-79). The o,p' isomerofDDT
(80), methoxychlor (81), and kepone (82) all have estro-
genic activity in rat uterine weight assays. p,p'-DDT
(Fig. 11) has an extremely low affinity for the estrogen
receptor, but the o,p' isomer ofDDT is activity and will
inhibit thebindingof[3H]estradioltoestrogenreceptors
in vivo (83) and in vitro (80,84). The related compound,
methoxychlor (Fig. 11), is estrogenic in the rat; how-
ever, its mono- and didemethylated metabolites, as would
be expected from the structure (c.f. the early work of
Dodds, Fig. 1), are capable ofinhibiting the binding of
[3H]estradiol to its receptor in vivo (85) and in vitro
(86,87).
Structure-Activity Studies in Vivo:
Correlation with Estrogen Receptor
Binding
There are many published reports on the structure-
activity relationships of steroidal and nonsteroidal es-
trogens. For clarity, therefore, only select studies will
be considered to illustrate relevantpoints. Dorfman and
Kindl (88) used a 3-day immature mouse uterine weight
test to determine the uterotrophic activity of 3- and/or
17-deoxy derivatives of estrone and estradiol and se-
lected alkyl derivatives. The enhanced oral activity of
the 17 a-ethinyl derivative of estradiol was confirmed,
but in general other alkyl substitutions on the steroid
nucleus were found to be adisadvantage. Using estrone
as the standard, substitution with methyl at C2, alkyl
at C4 or methylene at C16 all dramatically decreased
estrogenic activity (Fig. 12). Estra-1,3,5(10)-triene has
very low potency as an estrogen (Fig. 12). Potency is
improved by substitution at C17 with either a ketone or
hydroxyl; however, aphenolichydroxyl atC3iSthemost
0 (2.2)
(OH (
(I1) HO~?
estra-l, 3, 5 (10)-triene (0.3)
FIGURE 12. Structure-activity relationships of estrone. The struc-
ture-activity relationships of steroids in the 3-day immature mouse
uterine weight test using estrone as the standard. The relative
potencies are shown in parentheses using estrone equivalent to
100. Data adapted from Dorfman and Kincl (88).
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FIGURE 13. Relative binding affinities (RBAs) of several cyclopro-
pyl analogs of stilbene and stilbenediol. Data adapted from Pento
et al. (90).
important substitution (Fig. 12). This is consistent with
the subsequent observation (89) that the 3-phenolic hy-
droxyl is the most important substitution for binding to
the estrogen receptor.
Diethylstilbestrol has a high binding affinity for the
estrogen receptor (45). A series of interesting cyclo-
propane analogs has recently been prepared (90) and
their biological properties assessed. The relative bind-
ing affinities ofseveral compounds are shown in Figure
13. The cyclopropyl analog (compound 15) most closely
related to DES has low binding affinity (RBA 9) for the
receptor, whereasathree-membered oxygencontaining
ring was less detrimental (RBA = 80) (compound 12).
Substitution of the cyclopropyl derivative with two
chlorines increased the RBA (compound 13), and, as
previously observed, masking the phenols with acetyl
group decreased the RBA (compound 14). An interest-
ing biological observation with these compounds is that
they are all estrogens of different potency except com-
pound II, which is reported (90) to be a weak anties-
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FIGURE 14. Structure-activity relationships of nonsteroidal estro-
gens related to phytoestrogens. The dose necessary to produce an
increase of immature mouse uterine wet weight to 20 mg from a
control value of 10 mg is shown for each compound (oral admin-
istration). Data adapted from Micheli et al. (92).
trogen in the mouse. There are no published reports of
the structure-activity relationships ofthis cis cyclopro-
pyl derivative, but it is possible that potency, and pos-
sibly effectiveness as an antiestrogen, could be improved
by para substitutions with hydroxyl and an alkylami-
noethoxyside chain [this is a recurrent feature of non-
steroidal antiestrogens (91)].
The structure-activity relationship of the plant phe-
nolics has been compared with synthetic estrogens (92).
In Figure 14 the potency of various compounds was
determined as the minimum oral dose level required to
produce an immature mouse uterine weight of 20 mg
(control = 10 mg). The structural similarities between
diethylstilbestrol and the test compounds is empha-
sized. As might be expected, diacetylation does not af-
fect the potency of orally administered diethylstilbestrol.
The A3-isoflavens (compound 18) isequivalent is potency
to compound 17. However, there is a dramatic decrease
in potency with compound 22 which is related to the
triphenylethylene-type of long-acting estrogens previ-
ously described (c.f. Fig. 2). It is interesting to note
that the isoflavan-4-ol (compound 23) is slightly more
active thatitsdehydrated derivative, compound22. The
coumarin derivatives (compounds 19-21) show a broad
range of potencies. The low potency of compound 21 is
dramatically improved by creating an oxygen bridge to
form coumestrol (comparative dose level 0.25 mg). Acet-
ylation of coumestrol to form compound 19 does not
significantly decrease activity. Substitution of com-
B
(26)
(28)
CH3\
NCH2CH20
CH3/
ICI 47,699
FIGURE 15. Nonsteroidal estrogens
9 N ~- OCCH3
(27)
0
13 OCCH,
OCCH3
0
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0
OCCH3
CH3CO *
O (31)
0
OCCH3
CH3C0I 10
O cyclofenyl
pound 21 with an n-propyl group increases potency from
37 mg to 0.1 mg, but introduction of a single methoxy
group improves potency still further (compound 20) to
0.031 mg. This may be a pharmacokinetic effect to in-
crease the lipophylicity and increase the biological half-
life by preventing rapid conjugation. The isoflavanone,
daidzein (compound 24), has a low potency of the same
order as the isoflavanone compound 25.
Substituted triphenylethylene derivatives have been
studied extensively in vivo (31,32). Potency can be im-
proved by strategically located hydroxyls (31), and du-
ration of action can be increased with alkyl ether
derivatives (17,18). The most interesting observation,
however, is the finding that a strategically located al-
kylaminoethoxy side chain can produce either agonist
or antagonist actions. The principle is exemplified by
the cis and trans geometric isomers of tamoxifen or
clomiphene. Tamoxifen andenclomiphene (the trans iso-
mers) arebothpaitialestrogenagonistsintheimmature
rat with antiestrogenic properties (93-95). In contrast,
the cis isomers, ICI 47,699 (Fig. 15) and zuclomiphene,
are both estrogens (93-95). These types ofobservations
have been used to develop models to describe estrogen
and antiestrogen action in the rat (94,96). The impor-
tance of a strategically located alkylaminoethoxy side
chain for antagonist action has recently been illustrated
(97) with derivatives of the estrogen cyclofenyl (Fig.
15). Removal of the acetyl groups and substitution of
one phenol with apyrrolidinoethoxy side chainproduces
an estrogen antagonist (97).
9
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FIGURE 16. Hypothetical model for estrogen and antiestrogen bind-
ing to the estrogen receptor. Estradiol-17, is anchored at a phe-
nolic site (PS) with high affinity binding (HAB). Compounds without
a phenolic hydroxyl or without the correct stilbene-like structure
would have low affinity binding (LAB). The trans and cis geo-
metric isomers refer to: (A) tamoxifen (R = CH,, R2 = C,H5) and
enclomiphene (R = C2H5, R2 = Cl); (B) ICI 47,699 (R = CH3
R2 = C2H5) and zuclomiphene (R = C2H5, R2 = Cl). An anties-
trogenic ligand can bind to the receptor site so that the alkylam-
inoethoxy side chain can interact with a hypothetical antiestrogen
region (AER) on the protein.
Structure-Activity Relationships in
Vitro: Receptor Binding Models
We have described a hypothetical model ofthe ligand
interaction with the estrogen receptor. The model is
based upon the structural features that are necessary
to initiate or to inhibit prolactin synthesis in immature
rat pituitary cells in primary culture. The simple inter-
action ofestradiol-170 with a hypothetical binding site
on the estrogen receptor has been taken as a starting
point to evolve a model for drug-receptor interaction
that results in the stimulation or inhibition ofprolactin
synthesis (Fig. 16). The foregoing arguments apply for
the simple phenolic stilbene diethylstilbestrol.
We propose that the essentially planar estrogenic li-
gand first binds to the receptor via the phenolic group
which produces a high affinity interaction. This initial
point ofattachment guides the rest ofthe molecule into
the binding site. The ligand is then locked into the re-
ceptor and the tertiary changes that occur during this
process activates the receptor complex. The antiestro-
gens, tamoxifen and 4-hydroxytamoxifen, completely
inhibit estradiol-stimulated prolactin synthesis with po-
tencies consistent with their RBAs for the estrogen
receptor (51). It is interesting to point out that these
antiestrogens are partial estrogens (partial agonists) in
vivo (98) but in vitro there is no stimulation ofprolactin
synthesis. Overall, we have demonstrated that the in-
hibition of estradiol-stimulated prolactin synthesis by
antiestrogens is competitive and reversible with estra-
Log Concentrotion of Ligonds (M)
FIGURE 17. Inhibition ofthe binding of [3H]estradiol to rat uterine
estrogen receptors in vitro by different substituted triphenyl-
ethylenes desecribed in Fig. 15. The assay was conducted at 4°C
and incubation was for 18 hr. The RBAs in parentheses are cal-
culated as [(M) concn E2 for 50% inhibition/(M) concn competitor
for 50% inhibition] x 100.
diol, an effect that strongly suggests a mechanism via
the estrogen receptor (51).
Introduction of a phenolic hydroxyl into tamoxifen to
produce 4-hydroxytamoxifen increases receptor affinity
and antiestrogenic activity (53). 4-Hydroxytamoxifen
can bind with high affinity at the phenolic site on the
receptor so that the phenyl ring containing the aminoe-
thoxy side chain will extend away from the binding site
to interact with an "antiestrogenic region" on the re-
ceptor (Fig. 16). This prevents the tertiary changes
necessary for receptor activation so the complex is un-
able to initiate estrogenic events.
Among the triphenylethylenes, compounds that have
cis and trans geometric isomers are extremely impor-
tant for the development of a ligand receptor model
because the isomeric molecules encompass both estro-
genic and antiestrogenic properties. Although a geo-
metric requirement for estrogenic activity has been
stress-ed previously (93), these data derived from stud-
ies in vivo cannot exclude the possibility that the cis
isomers (zuclomiphene or ICI 47,699) are preferentially
metabolized to estrogens in the liver before binding in
the target tissue. Zuclomiphene and ICI 47,699 are both
estrogens in vitro (44).
To describe the interaction of the geometric isomers
with the estrogen receptor, the trans stilbene-like
structure oftamoxifen and enclomiphene could sit loosely
at the binding site, with low affinity, so that the phenyl
ring substituted with thep-alkylaminoethoxy side chain
is projected away from the binding site (Fig. 16). The
estrogenic ligands, zuclomiphene and ICI 47,699, with
their low affinity for the receptor, can create a trans
stilbene-like structure withthepara-substituted phenyl
ring. In this binding state, the aminoethoxy side chain
would lie next to the phenolic site of the receptor with
a weak interaction with the ether oxygen (Fig. 16).
There would be no interaction ofthe side chain with the
antiestrogenic region, and as a result, no inhibition of
estrogen action.
We have probed this model in a study of acetylated
triphenylbutenes (Fig. 15). For convenience the rings
are labeled A, B and C. The RBAs of the compounds
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FIGURE 18. Adaptation of Belleau's macromolecular perturbation
theory to describe the interaction of agonists, antagonists and
partial agonists with the estrogen receptor (ER). The phenol groups
on the ligand interact with the phenolic site (closed triangle) on
the ER and produce a high affinity interaction ifthe geometry of
the ligand is correct. E2 (agonist) induces a specific conformational
perturbation (SCP) whereas 4-hydroxytamoxifen (OHTAM antag-
onist) only induces a nonspecific conformational perturbation
(NSCP). Bisphenol (partial agonist) produces a mixture of SCP
and NSCP in the ER.
are shown in Figure 17. The unsubstituted triphenyl-
butene (compound 26) has the lowest affinity for the
receptor but substitutions in the A and C rings dra-
matically improves affinity. Compound 30 with the ace-
tyl in the equivalent position ofthe 3-phenolic hydroxyl
ofestradiol was the most active estrogen and the other
compounds without substitutions in ring B were all es-
trogenic in vitro with potency directly related to their
RBAs. Compound 31 has a high binding affinity for the
receptor but is completely antiestrogenic in vitro. Clearly
the aminoethoxy side chain is not the only substitution
in ring B that will prevent estrogen action. Cyclofenyl
falls into the same category in vitro (unpublished ob-
servation), but the cyclohexane ring demonstrates that
the stilbene structure is not essential for effective re-
ceptor interaction. Of interest, however, is the obser-
vation that the removal of the acetyl groups to give
bisphenolic compounds, produces partial agonists in vi-
tro, i.e., compounds that can partially stimulate estro-
gen action. However, co-administration with estradiol
causes adecrease inthe full estrogen response. We have
explained these observations on the basis of Belleau's
macromolecular perturbation theory (99). According to
Belleau's hypothesis, an agonist binds to the receptor
and produces a specific conformational perturbation
(SCP) and, as a result, the complex has an intrinsic
efficacy of 1. An antagonist binds to the receptor to
produce a nonspecific conformational perturbation
(NSCP) and a complex with an intrinsic efficacy ofzero.
Between these extremes, a partial agonist binds to the
receptorand producesanequilibriummixture ofagonist
and antagonist receptor complexes. Applyingthese def-
initions to the estrogen receptor (Fig. 18), estradiol (ag-
onist) binds with high affinity to the resting receptor
and induces an SCP that results in the ligand being
locked into the binding site. 4-Hydroxytamoxifen (an-
tagonist) wedges into the restingreceptor and only pro-
duces an NSCP. The bisphenol (partial agonist) interacts
at the ligand binding site, but while some ofthe recep-
tors can be induced to lock the ligand into the protein,
other ligand interactions are only able to induce an NSCP
in the complex.
Obviously further structure-activity relationship
studies are required to consolidate these hypothetical
views ofligand bindingto the estrogen receptorbinding
site. However, other approaches can be taken to probe
the estrogen receptor binding sites. Monoclonal and po-
lyclonal antibodies to the estrogen receptor can bind to
different sites on the protein. One monoclonal antibody,
D547, will react with both estrogen and antiestrogen
receptorcomplexes (100). Although the antibody cannot
discriminate between agonist and antagonist receptor
complexes, it can be used as a tool to examine their fate
within target tissues. In contrast, we have recently de-
scribed (101) the effect of a polyclonal antibody to the
estrogen receptor that can distinguish between the
binding ofestrogens and antiestrogens. The final proofs
of the differential binding of estrogens and antiestro-
gens to the estrogen receptor must come with the X-
ray crystallography of purified estrogen and antiestro-
gen receptor complexes. This approach will almost cer-
tainly be feasible during the next decade. Mastery of
techniques to clone the gene for the estrogen receptor
will permit the production of "industrial" quantities of
the protein for a biophysical investigation of drug-re-
ceptor interactions.
Summary of Structure-Activity
Relationships
The structural requirements for estrogen action are
different in vivo and in vitro. A general molecular skel-
eton for estrogen receptor binding compounds to pro-
duce effects in assays in vitro is shown in Figure 19.
The correct dimensions are necessary for an estro-
genic ligand to occupy the receptor binding site.
A strategically located phenolic hydroxyl, not im-
paired by alkyl substitutions in the ortho position, is
necessary for high affinity binding to the receptor and
potent estrogenic activity in vivo.
Alkyl substitution of the 3'-phenolic hydroxyl of an
estrogenic compound produces low affinity binding to
the estrogen receptorbut metabolic activation can occur
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FIGURE 19. Basic structural features required by a compound to
produceestrogenic, partial estrogenic orantiestrogenic actions in
vitro. The potency of the compound is determined by a strategi-
cally located phenolic group on a ring equivalent to the A ring of
the estrane steroid nucleus. Substitution of the phenol reduces
affinity for the estrogen receptor and consequently the potency of
the compound.
in vivo to produce potent estrogen action (mestranol to
ethinyl estradiol).
Alkoxytriphenylethylenes (DBE, TACE) have a long
duration of action because of a high solubility in body
fat. There is metabolic activation to the phenolic
derivatives.
A bisphenolic compound can occupy the receptor and
produce estrogen action in vivo (the metabolite ofmeth-
oxychlor, cyclofenyl). A stilbene-like structure is not
required, only a spacing group to occupy the binding
site.
Abisphenolic compound (withcorrectspacinggroups)
has a high affinity for the estrogen receptor but partial
agonist activity in vitro.
Extending a side chain (alkylaminoethoxy or acetyl)
away from the binding site in a bisphenolic compound
produces a binding ligand with antiestrogenic proper-
ties in vitro.
Nonsteroidal antiestrogens based upon triphenyle-
thylene with an alkylaminoethoxy side chain (tamoxi-
fen) are complete antagonists in vitro but partial agonists
in vivo.
Acetylated antiestrogens in vitro (cyclofenyl) are de-
acetylated in vivo to produce full estrogen action; bis-
phenolic triphenylethylenes that are partial agonists in
vitro are full agonists in vivo.
Several of the general structural features that are
required for estrogenic activity may aid the investiga-
tion of novel compounds in the future.
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